ALK and non-small cell lung carcinoma: The NCCN guideline recommends plasma testing to evaluate EGFR, ALK, ROS-1, BRAF, RET, and MET alterations when there is insufficient tissue material to guide the use of target therapies in patients with advanced or metastatic NSCLC.11 The results demonstrated that NGS ctDNA has a high accuracy to detect the six oncogenic driver mutations.